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The research in extracellular vesicles (EVs) has been rising during the last decade. However,
there is no clear consensus on the most accurate protocol to isolate and analyze them.
Besides, most of the current protocols are difficult to implement in a hospital setting due to
being very time-consuming or to requirements of specific infrastructure.Thus, our aim is to
compare five different protocols (comprising two different medium-speed differential cen-
trifugation protocols; commercially polymeric precipitation – exoquick – acid precipitation;
and ultracentrifugation) for blood and urine samples to determine the most suitable one
for the isolation of EVs. Nanoparticle tracking analysis, flow cytometry, western blot (WB),
electronic microscopy, and spectrophotometry were used to characterize basic aspects
of EVs such as concentration, size distribution, cell-origin and transmembrane markers,
and RNA concentration. The highest EV concentrations were obtained using the exoquick
protocol, followed by both differential centrifugation protocols, while the ultracentrifuga-
tion and acid-precipitation protocols yielded considerably lower EV concentrations.The five
protocols isolated EVs of similar characteristics regarding markers and RNA concentration;
however, standard protocol recovered only small EVs. EV isolated with exoquick presented
difficult to be analyzed with WB.The RNA concentrations obtained from urine-derived EVs
were similar to those obtained from blood-derived ones, despite the urine EV concentra-
tion being 10–20 times lower. We consider that a medium-speed differential centrifugation
could be suitable to be applied in a hospital setting as it requires the simplest infrastructure
and recovers higher concentration of EV than standard protocol. A workflow from sampling
to characterization of EVs is proposed.
Keywords: extracellular vesicles, protocol standardization, clinical application, nanoparticle tracking analysis,
flow cytometry, translational research, urine
INTRODUCTION
Extracellular vesicles (EVs) are membrane-bound particles shed
from almost all cell types, carrying components from the cell
donor such as lipids, proteins, RNA, glycolipids, and metabolites
(1). It has been suggested that they play several biological roles
like, for example, antigen presentation without cell contact (2),
microenvironment modification, and distant cell education (3),
roles that have been encompassed under the term “cell-to-cell
contact-free communication”. In turn, their biological functions
have been related to many pathophysiological processes, the most
studied being cancer (4), immune-mediated diseases (5), and
cardiovascular disorders (6).
A widespread concern in the biomedical research community is
the gap between the basic research carried out in the laboratories
and the clinical setting where the new biological information
should have a direct impact. Many researchers have directed their
efforts toward bridging that gap and look for ways to trans-
late lab findings into clinical solutions, emerging therefore the
translational research. The translational research on EVs is not
foreign to this goal: the current knowledge about EVs, mostly
developed in vitro, has been proposed to be applied in a daily hos-
pital routine giving answers to specific health queries (7–13). This
possible application ranges from diagnostic to therapeutic objec-
tives, including disease monitoring and the search of prognostic
biomarkers, among others. But are the hospitals technologically
prepared to employ EVs studies routinely?
The main steps for studying EVs and applying the results
involve sampling (blood, urine, saliva, cerebrospinal fluid, joint
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fluid, breast milk, ascitic fluid, etc.) and isolation, to be afterward
characterized and analyzed their cargo and, finally, give a poten-
tial clinical interpretation and application. Concerning the first
steps, sampling and pre-analytical parameters have been widely
studied and are close to reach a consensus (14, 15). However,
isolation is still a critical step due to several reasons. First, the
methods to isolate EVs are currently highly diverse [reviewed by
Momen-Heravi et al. (16) and Witwer et al. (17)] and depending
on which one is employed, the results can be considerably differ-
ent, even having started from the same sample. At the moment,
most of them are based on EV density, including differential
centrifugation steps from low speeds (1,500× g ) to ultracentrifu-
gation (>100,000× g ), combined or not with density gradient
and/or filtration. Precipitation using polymers and immunoaffin-
ity agglutination are also widely used. Recently, the size-exclusion
chromatography (18) and chip devices (19) have been added to the
rest of methods. All of them, either by themselves or in combina-
tion, yield a solution enriched in EVs in different extents. Finally,
depending on several factors such as time consumption, cost,
friendly use, and reproducibility, these methods are or not able
to be applied in a daily clinical routine. Despite lots of important
works shedding light on this field, there is still a lack of consen-
sus (20) evidencing the urgent need of standardized protocols
appropriate for hospitals.
Considering the problems and needs regarding the use of EVs
in a clinical setting, we established the following objectives for the
present study: to compare several protocols for EVs isolation and
to analyze which of them could be the most suitable one to be used
in daily clinical setting.
MATERIAL AND METHODS
Blood and urine are the most widely used samples in a hospi-
tal setting, as they provide useful information and they are easy
to obtain with minimally invasive techniques. Thus, we decided
to isolate EVs from these biofluids as the starting point for EV
isolation.
Samples were collected from 10 healthy individuals (5 males
and 5 females; average age= 37± 8 years old) and stored according
to the criteria of the Donostia node of the Basque Biobank. All sub-
jects gave written informed consent and the study was approved
by the Hospital Ethics Committee.
Donors underwent a questionnaire about recent exercising
(within the last hour), drugs/medication intake, ovulatory cycle,
acute illness, and sleeping hours.
The workflow followed in the present work is summarized in
Figure 1.
BLOOD
Peripheral blood samples were collected at the Donostia University
Hospital at 8:30 a.m. on fasting and were processed separately
(without pooling them) within the first hour. After discarding the
first milliliter, blood collection was done by venipuncture with a
FIGURE 1 | Comparison of five protocols for EVs isolation. Blood and urine samples were isolated with five different protocols (seeTable 1 for more details)
and then characterized with five outputs methods.
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21-gage needle in a 10-ml EDTA tube,a 3.8-ml citrate tube,and a 8-
ml serum tube [Vacutainer, Becton Dickinson (BD)], kept upright
and centrifuged at 2,500× g during 15 min. The supernatant was
recovered to obtain platelet-poor plasma (PPP) or platelet-poor
serum, being these samples the starting point for all the protocols.
Besides, additional blood samples were collected in EDTA and
serum tubes to perform a hemogram and obtain protein and lipid
profiles in the core laboratory of the Hospital. The parameters
tested are shown in Table 1.
Although we collected plasma and serum from peripheral
blood, the present work is focused on plasma. In this sense, we
are going to refer only to plasma in all the sections of “Materials
and Methods” for the sake of simplicity. The results and discus-
sion of blood-derived EVs will be also centered on plasma and
only relevant results will be presented in the case of serum.
URINE
Sixty milliliter-first void of the day was collected in aseptic condi-
tions by each individual at home, kept at 4°C until their processing
with an average time of 2.7 h between collection and processing.
Ten milliliters were sent to the core laboratory for the analysis
of the most common urine parameters (Table 1). The rest was
aliquoted in five tubes of 10 ml and centrifuged at 2,500× g for
15 min in order to obtain cell-free urine (CFU).
EV isolation protocols
The protocols described below are summarized in Table 2.
Centri2500. This method is based on the protocol published by
Lacroix and colleagues (14). Briefly, 1.3 ml of PPP or 9.5 ml of
CFU obtained at the first centrifugation are centrifuged again at
2,500× g during 15 min to get 1 ml of platelet-free plasma (PFP)
or 9 ml of debris-free urine (DFU). Both PFP and DFU sam-
ples were stored at −80°C for later use. When needed, samples
Table 1 | Lab parameters analyzed in blood and urine samples.
Blood Creatinine (mg/dl) 0.9±0.3








Platelet count (10e3/µl) 238.7±56.7
Lymphocyte count (10e3/µl) 1.9±0.5
Urine Density (g/l) 1019.4±7.7
pH 6.0±0.9
Glomerular filtrate (mL/min/1.73 m2) 84.3±15.5
Erythrocyte count (ery./µl) Negative
Leukocyte count (leu./µl) Negative
Epithelial cell count (cells/µl) Negative
Values represent the mean±SD from the 10 healthy controls.
were thawed on ice and centrifuged once again at 20,000× g dur-
ing 20 min to pellet the EVs, discarding 900µl of supernatant,
following the protocols described by Ashcroft and colleagues (21)
and Jayachandran and colleagues (22). The pellet containing the
EVs was resuspended in 100µl of PBS (GIBCO, Life Technologies)
filtered twice through a 0.22µm-pore filter.
Centri13000. This method is based on the protocol published by
Dey-Hazra and colleagues (23) and Dignat-George and colleagues
(24). In brief, it is a modification of the previous method where
the second centrifugation performed on the 1.3 ml of PPP was
done at 13,000 during 2 min to obtain PFP or DFU. The rest of the
protocol was the same as the previous one. To note, this protocol
was not performed for urine samples.
Exoquick. The basis for this method lays on the precipitation of
EVs using a commercial agglutinating agent and was performed
following the manufacturer’s instructions. In summary, 63µl or
2 ml of exoquick TC (System Biosciences) were added either to
250µl of PPP or to 9.5 ml of CFU, respectively, and the mix
was incubated overnight at 4°C with no rotation. Then, two cen-
trifugation steps were performed at 1,500× g for 30 and 5 min,
respectively, to sediment the EVs and the pellet was resuspended
in 200µl of PBS. It needs to be noted that, although the first ver-
sions of the manufacturer’s instructions included a filtering step
using a 0.45µm-pore filter, it was removed in the latest version
and, thus, it has not been included in our protocol.
Salting out. This method has been adapted from the proto-
col recently published by Brownlee and colleagues (25) and it is
based on the precipitation of EVs through an aggregate of sodium
acetate 1 M, ph 4.75. A centrifugation was performed on 1.3 ml
of PPP or 9.5 ml of DFU at 13,000× g for 30 min; we collected
the supernatant (1 ml of PPP or 9 ml of DFU), added sodium
acetate (dilution 1/10), and incubated on ice for 60 min and, sub-
sequently at 37°C for 5 min. The dilution was then centrifuged at
5,000× g during 10 min and the resulting pellet was washed with
Table 2 | EV isolation methods compared in this work.
Method Isolation principle Steps
Centri2500 Differential centrifugation 2500×g 15′×2+20,000×g
20′ to pellet the EVs
Centri13000 Differential centrifugation 2500×g 15′+13,000×g
2′+20,000×g 20′ to pellet
the EVs
Exoquick Agglutination–precipitation 2500×g 15′+ agglutination
with exoquick+1500×g 30′
and 5′ to pellet the EVs
Salting out Precipitation 2500×g 15′+13000×g
30′+ acid precipitation+
5000×g 10′ to pellet the EVs
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a buffer with sodium acetate at 0.1 M to be finally resuspended in
200µl of PBS.
Standard. This is the method considered as the standard isola-
tion protocol nowadays (26). The starting point was 1.3 ml of PPP
or 9.5 ml of CFU that were filtered through a 0.22µm-pore filter
and centrifuged at 10,000× g during 30 min to obtain either PFP
or DFU. These were ultracentrifuged at 100,000× g in an Optima
MAX tabletop centrifuge (Beckman Coulter) during 75 min. The
resulting EV pellet was resuspended in 200µl of filtered PBS.
EV detection and characterization methods
Nanoparticle tracking analysis. The size distribution and con-
centration of EVs were measured using a NanoSight LM10
machine (NanoSight). All the parameters of the analysis were set
at the same values for all samples and 1 min-long videos were
recorded in all cases. Background was measured by testing filtered
PBS, which revealed no signal. The EVs obtained from PFP (5µl)
were diluted with filtered PBS to 1:150 and the ones obtained from
DFU (5µl) to 1:50. For each sample, two measurements were per-
formed. It is necessary for a minimum of 200 tracks (movements
of single particles recorded by a camera) to obtain valid results.
The following parameters were measured: the mean and mode of
the size distribution and the concentration of EVs (27).
Flow cytometry. The labeling and gating of EVs were performed
as described by Sáenz-Cuesta and colleagues (28). Briefly, 4µl
of CD61-PE (Cytgonos) or CD45-PE (BD) monoclonal antibod-
ies were mixed with 40µl of resuspended EVs and incubated for
20 min. Next, labeled EVs were washed once with 300µl of filtered
PBS, resuspended in further 200µl of filtered PBS and acquired
at low rate in a FACS Canto II flow cytometer (BD). Side and
forward scatter were measured on a logarithmic scale with the
threshold set at 300 for each parameter to avoid instrument noise
(background signal). Then, the lower limit was defined with the
exclusion of background noise given by the signal of PBS filtered
twice. To define the upper limit of the total MP gate, 1-µm non-
labeled polystyrene latex beads were used (Sigma-Aldrich). The
events that appeared in this region were included in the total
EV count and were further analyzed for specific labeling (posi-
tive for PE marker). We defined CD61+ EVs as platelet-derived
EVs (PEV) and CD45+ EVs as leukocyte-derived EVs (LEV). The
total and cellular origin-specific EV concentrations were obtained
using Trucount™ tubes [BD; Ref. (28)].
Western blot. Primary CD133 (Miltenyi Biotec S. L) and CD63
(Santa Cruz Biotechnology, Inc.) antibodies were used to study
specific EV transmembrane markers. Mouse and rabbit HRP-
conjugated antibodies (Cell Signaling) were employed as sec-
ondary antibodies. All protein procedures were done at non-
reducing conditions. Samples (10µl of PBS-resuspended EVs)
were incubated at 95°C for 5 min, separated in SDS polyacrilamide
gels, and transferred to nitrocellulose membranes (GE Health-
care). Membranes were blocked for 1 h at room temperature with
5% milk (w/v) in TBS solution with 0.1% Tween-20 (T-TBS) and
incubated in the same solution with primary antibodies overnight
at 4°C. Primary antibodies were washed with the T-TBS solution
and incubation with secondary HRP-conjugated antibodies was
performed at room temperature for 1 h in the same solution used
for the primary antibodies. After washing with T-TBS solution,
the HRP signal was detected by a chemiluminiscent reaction with
the SuperSignal West Dura Extended Duration Substrate (Thermo
Fisher Scientific, Inc.).
RNA isolation. A 185µl-aliquot of resuspended EVs was used
to extract total RNA with the miRNeasy serum/plasma kit (Qia-
gen). RNA concentration was measured with the nanodrop 1000
spectrophotometer (Thermo Scientific).
Cryo-electron microscopy. The cryo-electron microscopy (EM)
was performed following the protocol used by Perez and colleagues
(29). Briefly, 10µl of EV preparations were directly adsorbed
onto glow-discharged holey carbon grids (QUANTIFOIL Micro
Tools GmbH). Grids were blotted at 95% of humidity and rapidly
plunged into liquid ethane with the aid of VITROBOT (Maas-
tricht Instruments B). Vitrified samples were imaged at liquid
nitrogen temperature using a JEM-2200FS/CR transmission cryo-
electron microscope (JEOL) equipped with a field emission gun
and operated at an acceleration voltage of 200 kV.
Statistical analysis
The statistical analysis was performed with PASW Statistics v18.0
(SPSS Inc.). Kolmogorov–Smirnov and Shapiro–Wilk tests were
used to check normality of distributions. As all of the variables
were shown to follow a normal distribution, T -tests were applied
to assess differences between the groups. Pearson’s R correlations
were computed to explore the relations between lab parameters
and some EV parameters. Both differences between groups and





Extracellular vesicles concentration was measured using two inde-
pendent methods: nanoparticle tracking analysis (NTA) and con-
ventional flow cytometry (FC). It is to be noted that the lower
detection limits are different, being 50 nm for NTA (27) and
around 400 nm for FC (30).
Nanoparticle tracking analysis
When using NTA, the software requires a minimum of 200 tracks
during the capture time of the video. In the case of the samples
processed with the salting out and standard methods, only few of
them reached that minimum. This was critical for NTA analysis
causing a high variability on these samples (Figures 2A,E). The
exoquick method yielded higher EV concentration values than
any other method used. We obtained four times higher EV con-
centration with exoquick than with centri2500 (p= 0.007) and
centri13000 (p= 0.05) and 23 times higher concentration values
comparing to salting out (p= 0.002) and standard (p= 0.002)
methods (Figure 2A). No significant differences have been found
either between the EV concentrations obtained with the centri2500
and centri13000 methods, or between those yielded by the stan-
dard and the salting out methods. However, there are significant

























































Sáenz-Cuesta et al. EVs isolation in a hospital setting
FIGURE 2 | Results of the comparison of five protocols for isolation of
EVs. Box plots show EV concentration measured by nanoparticle tracking
analysis [NTA; (A,E)] or conventional flow cytometry [FC; (B,F)], EV size
distribution measured by NTA (C,G), and concentration of RNA yielded from
EVs (D,H). In the left column, the results from plasma-derived EVs are shown
and in the right column those from urine. For statistical significance, see text.
All bars represent mean values with SD except for size plots (C,G) that bars
indicate mode with SD.
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differences between these two groups of methods (Figure 2A)
obtaining a p value of <0.001 for both centri2500 vs. salting out
and standard and 0.002 and <0.001 for centri13000 vs. salting
out and standard respectively. Regarding the EVs isolated from
serum, they were obtained using the exoquick, centri13000, and
standard protocols and we have observed that, as it happens with
plasma, the exoquick method yields significantly higher EV con-
centrations than the other two methods. When we compared
serum and plasma considering all isolation methods, 3.4 times
higher EV concentrations have been observed for serum using
exoquick and 1.3 times higher ones when using centri13000, but
these comparison did not reach statistical significance (see Table
S1 in Supplementary Material).
Flow cytometry. Although the EV concentrations obtained using
FC were lower than those obtained by NTA, there was good corre-
lation between the concentration profiles yielded by each approach
when using the averages for each isolation method for the compari-
son (R= 0.99; p< 0.001). Nevertheless, no significant correlations
were observed when performing the analysis for each isolation
method separately. Besides, significant differences were observed
between all isolation methods except for centri2500 vs. centri13000
and salting out vs. standard (Figure 2B).
EV size
There is great similarity between the modes of EV size obtained
with the different isolation protocols ranging from 150 to 277 nm,
average of mode size: 228 nm (Figure 2C). In accordance to
these results, the EM images show EVs with a size between 100
and 200 nm (Figure 3A). Significant differences in size only exist
between the EVs isolated with the standard method when com-
pared to those obtained through the centri2500 and centri13000
methods, being the former the smallest of all at 158.7 nm. Besides,
the EM images of the EVs obtained with exoquick present sev-
eral filamentous aggregates and other globular structures not
considered EVs.
RNA concentration in EVs
Despite the salting out and the standard methods being the ones
that yield the lowest EV concentrations, the highest RNA concen-
trations have been obtained through these methods (19.5± 5.7
and 23.6± 8.2 ng/µl, respectively), higher than with the centri2500
and centri13000 methods (14.5± 3.3 and 12.5± 4.5 ng/µl, respec-
tively). It is remarkable that exoquick yields 18.1± 6.0 ng/µl of
RNA, despite having isolated around 23 times more EVs than the
salting out and standard methods (Figure 2D).
Western blot
The detection of EV markers through western blot (WB) was used
as a confirmation of the presence of EVs in the solutions obtained
at the end of the isolation protocols. The objective was not to per-
form a detailed characterization of the markers, but to look for
differences in their detection between the different methods.
Great inter-method variability has been observed. Briefly, CD63
detection is better in EVs isolated from plasma than in those
obtained from serum. Among the plasma-derived EVs, CD133
showed better signal for centri2500 and centri13000 than for the
FIGURE 3 | Characterization of EVs. (A) Two images of electronic
microscopy of EVs (pointed with red arrows) derived from plasma and
urine. Scale bar represents 100 nm. To note, in the image of urine-derived
EVs, it is observed contaminants not seen in the plasma-derived one.
(B) Western blot analysis using the specific EV markers CD133 and CD63.
In CD133 plasma samples, the specific bands are pointed with red arrows.
Positive control was performed with NHC-2 p10 cell line.
salting out and the standard protocols. The detection of CD133
was also worse in serum-derived sample than in plasma-derived
samples. Nonetheless, CD133 detection was better in urine-
derived EVs than in the samples obtained from blood (Figure 3B).
It is of note that the EVs isolated with exoquick could not be used
for WB marker analysis using plasma samples due to be impossible
to dissolve its pellet.
URINE
EV concentration
In the NTA analysis of the EVs isolated from urine, we have
observed that the concentrations were as low as the great majority
of the samples have not reached the minimum track-count. Thus,
once again the interpretation of NTA data from urine-derived EVs
was carried out with caution. Exoquick was the method that yields
the highest EV concentrations from urine using either NTA or FC,
followed by the standard protocol. The centri2500 and salting out
protocols yielded very similar concentrations. Figures 2E,F sum-
marizes the EV concentration results from the application of the
different protocols to urine as measured by NTA and FC, respec-
tively (for p values, please see Table S1 in Supplementary Material).
In summary, using both NTA and FC, we obtained a similar con-
centration profile to that of blood but with 10–20 times lower
concentrations.
EVs size
The modes of the size distributions obtained with the different
protocols were similar and, the average of these modes (207 nm)

























































Sáenz-Cuesta et al. EVs isolation in a hospital setting
was similar to that achieved in blood samples (228 nm). As it hap-
pened with blood samples, the smaller EVs were isolated with the
standard method (162.5 nm) comparing to the other protocols
(Figure 2G). The results of the size assessed by NTA were, once
again, consistent with the observations done using EM. In most of
these urine samples, the number of contaminating particles that
could not be considered EVs was higher than in blood (Figure 3A).
RNA concentration in EVs
Higher RNA concentrations were obtained from EVs isolated with
the standard (33 ng/µl) and salting out (25.9 ng/µl) methods and
even higher than the concentrations obtained from blood samples,
where the EV concentration was from 10 to 20 times higher than
in urine (Figure 2H).
Western blot
The EV samples isolated from urine using exoquick, in contrast
to the ones isolated from plasma, can be used for marker analysis
with WB (Figure 3B).
In brief, CD133 detection in urine-derived samples is better
with precipitant agents (exoquick and salting out methods) than
with centrifugation methods, although the standard shows bet-
ter results in urine and serum than in plasma. On the opposite,
CD63 signal is weak in urine-derived samples compared to that of
plasma- or serum-derived samples for all methods.
CORRELATION WITH LABORATORY PARAMETERS
We have also tested whether the EV concentration values obtained
with different methods and the different types of samples (plasma,
serum, or urine) could be reflected in some of the lab parameters
measured in blood and urine, especially the ones that are related
to the main components of EVs, i.e., lipids and proteins. Fur-
thermore, the analysis of these correlations would serve to test a
possible interference in EV quantification produced by these para-
meters, a phenomenon that has been previously described (31).
Interestingly, a significant correlation has been observed
between the concentration, as measured by NTA, of the EVs
isolated from plasma with the centri13000 method and the
total cholesterol (R= 0.953; p= 0.003) and LDL concentrations
(R= 0.935; p= 0.006) in blood. We have also detected a signifi-
cant correlation between the NTA-measured concentration of the
plasma-derived EVs isolated using the standard method and the
concentration of triglycerides in blood (R= 0.789; p= 0.007).
No significant correlation has been found between the concen-
trations of the EVs of specific cell-origins and the concentrations of
the respective source cells in blood. The concentrations of CD61+
(platelet origin) or CD45+ (leukocyte origin) EVs are plotted in
Figure S1 in Supplementary Material.
In regard to the EVs isolated from urine, the only significant
correlation we have observed is the one between the density of
urine and concentration of EVs, measured with both NTA and
FC, isolated with the salting out protocol (R= 0.841; p= 0.002 for
NTA and R= 1.000; p=> 0.001 for FC).
DISCUSSION
In the present work, we have studied and compared several widely
used methods for the isolation of EVs, including differential cen-
trifugation, agglutination, precipitation, and the one considered
the standard that includes ultracentrifugation (plus filter). All
methods under study can be applied using relatively simple tech-
nology, with the exception of ultracentrifugation, which must be
performed with an instrumentation that, even if it is easy to use,
is not usually found in most hospital laboratories. The election
of one or other method as the most suitable one to be used in a
hospital setting greatly depends on the goals to be reached with
the method, which could be, among others: to maximize the final
EV concentration, to obtain high levels of purity as measured by
markers and several classical characteristics of EVs, to select one of
the three fundamental types of EVs (exosomes, microvesicles, and
apoptotic bodies) or to get the less time and/or money consuming
protocol. We have set the first two as preferential aims, leaving the
rest out of the scope of this work.
ISOLATING EVs
We have observed that,besides being the method that can be imple-
mented most easily (it is quick and relies on very little technology),
exoquick is also the method that yields, in a statistically significant
manner, the highest concentration of EVs (as measured by NTA
and FC) compared to the other four isolation protocols. The EV
quantity is even higher when using serum as the starting sam-
ple. On top of that, to dissolve the pellet obtained using exoquick
from serum-derived samples is notably easier than plasma-derived
samples. Nonetheless, the considerably higher EV concentrations
obtained with exoquick (23 times higher than those obtained with
the standard protocol) could be linked to the aggregation and pre-
cipitation of other elements in suspension in the sample that are
not necessarily EVs; as it can be observed in the images obtained by
EM. Taylor and colleagues (32) demonstrated that using exoquick
more EVs are isolated than using ultracentrifugation (standard),
chromatography, and magnetic beads, and with a higher purity of
exosomal RNA and proteins. Our results only partially coincide
with the observations of Taylor and colleagues, as the RNA con-
centration we obtained with exoquick is lower than that yielded
by the standard method. In another study that compared the exo-
quick method with the standard method, the authors concluded
that a combination of these two methods is the protocol that yields
the highest EV counts, although exosomes of higher quality were
obtained combining the standard method with the sucrose density
gradient (33). Yet, Exoquick is the most expensive of the methods
used in the present work.
The differences in EV concentration between the two centrifu-
gation methods (centri2500 and centri13000) are not statistically
significant. The sole differences are that the cluster of EVs observed
by FC in the FSC/SSC dotplot shows less debris around in the case
of centri13000 and that the EVs isolated with this method also
show a stronger labeling of CD63 in WB. The conclusions reached
at the workshop of the Scientific and Standardization Commit-
tee of the International Society of Thrombosis and Hemostasis to
promote the use of these protocols (15) and aimed to reducing
the variability due to a resuspension of the pellet (24). Nonethe-
less, in our opinion, the main drawback of this proposal is that, as
the EVs are not concentrated in a pellet–like, we performed with
the final centrifugation at 20,000× g, a pellet-washing step cannot
be introduced and EVs are maintained in dissolution along with
many other contaminating particles such as protein aggregates.
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Regarding size, very similar EV sizes have been obtained with
these two methods, even when measuring size on EM imagery.
These suggest that the second centrifugation is probably not that
critical and could vary, at least between 2,500 and 13,000× g, with
the objective of eliminating cell debris. Moreover, these meth-
ods collect six times higher EV concentrations than the standard
protocols, what can be explained by the fact that they are less
restrictive methods. Finally, the technical requirements for the use
of these methods are usually met in most basic research labo-
ratories and they are considerably less time-consuming than the
standard method.
Ultracentrifugation is nowadays the “gold standard” method
for the isolation of EVs, fundamentally exosomes. With the aim
of finding alternative methods to this protocol, Brownlee and col-
leagues (25) have recently described a new method called salting
out, based on the precipitation of EVs using the aggregate of
acetic acid. In the present study, the salting out method yielded
the lowest EV concentrations when compared to the other proto-
cols, although showing similar values to those obtained with the
standard method as the authors of the aforementioned article also
pointed. It has to be noted, though, that Brownlee and colleagues
isolated EVs from cell culture supernatants and, thus, comparisons
with the present work must be done with caution.
Although out of the main objectives of this work, we have also
compared the EVs isolated from three different types of samples:
plasma, serum, and urine. We have observed that higher concen-
trations of EVs are obtained from serum than from plasma for all
methods, and 10–20 times more, depending on the method, when
comparing plasma with urine. As comparisons between serum
and plasma have been performed by other authors (34, 35), we
just present our results.
The EV size distributions that we have obtained with the exo-
quick, salting out, centri2500, and centri13000 methods are very
similar, being the EVs with a size below 200 nm the most abundant.
Nevertheless, a cluster of EVs can be observed with a size around
500–600 nm that could represent the population of microparti-
cles. On the contrary, the standard method isolates smaller EVs as
it uses a 0.22µm-pore filter leaving out the bigger EVs (micropar-
ticles and apoptotic bodies). We agree with Jy and colleagues (36)
that the capacity of the first four methods to isolate the bigger EVs
can be useful when applying these protocols in clinical practice.
In the case of urine, very low EV concentrations have been
obtained with the five methods and, thus, we recommend not to
dilute or to dilute very little urine-derived samples before ana-
lyzing them by NTA, FC, and WB. Once again, exoquick was
the method that yields the highest concentrations according to
other authors’ results (37). Certainly, when using urine samples,
it would be of great consequence to avoid contaminating proteins
such as Tamm–Horsfall, which traps EVs but it can be removed
with the simple addition of dithiothreitol and heat (38). Further-
more, Rood et al. (18) suggest that the most effective method in
terms of purity for urine-derived EVs to undergo downstream
proteomic analysis is the combination of ultracentrifugation fol-
lowed by size-exclusion chromatography. The major disadvantage
of this protocol would be that it is time-consuming and it requires
of specific infrastructure that make it difficult to be compatible
with clinical applications.
DETECTING AND CHARACTERIZING EVs
During the processing, after the centrifugation at 20,000× g for
20 min, a fine lipidic layer could be observed in some of the sam-
ples. This corresponded to a FC image with a higher EV density
(data not shown). Nevertheless, the presence of this layer did not
show correlation with NTA results. It is well known that the density
and size of the EVs can overlap with these of lipoproteins and this
can produce artifactual results in FC analyses (31). Besides, we have
found positive correlation between the LDL levels in blood and the
concentration of EVs obtained with several methods, which sug-
gests that, when isolating the EVs, some LDL particles are also
dragged and counted as EVs. One approach to measure the purity
of EVs is the EV/protein ratio (39), a method that is easy to use and
yield reproducible results. However, it remains out of the scope of
the present work.
The most widely used methods for the quantification of EVs are
NTA and FC. According to our data, the results yielded by these
two methods are not interchangeable, probably because the size
ranges that they can analyze are different. The correlation between
the two methods would be better studied using only the concen-
tration of EVs larger than 400 nm, as this is the minimum size
for the FC analysis. Nevertheless, we have looked for correlation
using concentration results for EVs larger than 400 nm in another
dataset (data not shown) and we have found none. Thus, we con-
sider that these two quantification methods do not exclude each
other but are complementary, as NTA gives more accurate counts
but FC allows the characterization of distinct cellular origins.
From the comparison of the methods that we have used to
study the size of EVs, we can conclude that, while the NTA, as it
allows to recover information from individual particles, allows to
obtain and compare size distributions, EM provides more robust
information on the characteristics of EVs but size distributions
cannot be obtained through EM imagery. Furthermore, NTA has
the advantage of performing a multiple analysis in few minutes.
Tetraspanins have been widely used as general markers of EVs;
however, during the last years, some works have provided evidence
that not all vesicles express them at the same levels suggesting that
different EV subsets could coexist in the same pellet (40, 41). In the
case of urine-derived EVs, our results present low or undetectable
levels of CD63 except for those obtained with the standard pro-
tocol (Figure 3B). Both the previously described lack of CD63 in
urine-derived EVs larger than 100 nm (42) and its expression in
EVs obtained with the standard protocol (43, 44) are congruent
with our results. In the other hand, we found expression of CD133
with all the methods. In agreement with other authors, we con-
cluded that the presence of CD133+/CD63− EVs demonstrate the
recovery of the large ones that usually express this pattern of mark-
ers (45–47). Moreover, Bobrie and colleagues described the CD63
as a variable marker found only in a fraction of the sucrose gradi-
ent (40), which implies questioning the use of CD63 as a standard
EV marker (48). Finally, the expression of CD63 is susceptible to
SCORT regulation leading to the blockage of the budding of this
EV subset (49) and this mechanism could hypothetically be more
frequent in urine-derived EVs. Regarding to plasma-derived EVs,
the detection of the opposite pattern (CD133−/CD63+) in the
EVs obtained with standard protocol unravel the isolation of a
specific EV fraction, being probably only exosomes (46).

























































Sáenz-Cuesta et al. EVs isolation in a hospital setting
FIGURE 4 | A proposed workflow for the study of extracellular vesicles (EVs) in a hospital setting.
(Continued )

























































Sáenz-Cuesta et al. EVs isolation in a hospital setting
FIGURE 4 | Continued
Patients visited during the morning in the hospital, preferentially on fasting,
undergo sample collection of 30 ml of blood (EDTA or citrate) and 50 ml of the
first void urine. Immediately, 15 ml of blood and 40 ml of urine are destined to
the EV isolation protocol to obtain a pellet and the rest 15 and 10 ml are sent
to the core laboratory to analyze biochemical parameters. The obtained EV
pellet resuspended in PBS could optionally be frozen at −80°C and continue
when required. Next, the detection/characterization of EV is divided in two
levels for quantification, size [nanoparticle tracking analysis (NTA)], and initial
characterization with flow cytometry (FC) followed by an extensive
description with western blot (WB) and electronic microscopy (EM).
Subsequently, the analysis of EV cargo with several omics platforms allows
the identification of specific compounds carried by EVs. EVs detection and
their cargo analysis could optionally be referenced, at least during the initial
setting of this workflow, to an expert EV laboratory in order to provide a
validation of the results and pass a quality control test. Finally, the detected
molecules are interpreted in the whole context of the patient with the aim of
identifying biomarkers or a target for a putative therapy. The results provided
by the study of EV are applied back to the patient improving the diagnosis or
course of the disease.
Regarding the RNA concentrations yielded by the different EV
isolation methods, we have observed great variability. Although
Taylor and colleagues conclude that exoquick isolates more than,
among other methods, ultracentrifugation (32), we have observed,
unexpectedly, that the RNA concentrations obtained with the dif-
ferent methods are very similar, despite the notable differences in
EV concentrations. Surprisingly, high RNA concentrations were
obtained from urine (especially when using the salting out and
standard methods), concentrations similar to or even higher than
those obtained from plasma and serum, regardless of EV concen-
trations being between 10 and 20 times lower. These results lead
us to think that, as we have not used RNAses, we are measuring
the concentration not only of the RNA contained in the EVs but
of the free RNA. In a position paper of the International Society of
Extracellular Vesicles, the authors suggest that the use of RNAses
only removes the free RNA not specifically bound to EVs, while
their use in combination with proteases also removes the nucle-
oproteic complexes (50). In any case, if the final objective is to
use the RNA as a source of potential biomarker, we believe that it
would be useful to preserve not only the RNA inside the EVs but
the RNA stuck to their membrane.
EVs FROM BENCH TO BEDSIDE
The importance of the study of EVs in a hospital setting to com-
plement the diagnosis and prognosis of several diseases has been
well demonstrated (51–53). Moreover, their application in ther-
apeutic approaches has already been tested in clinical trials with
promising results (54). Nonetheless, we believe that the workflows
from the collection of the samples aimed at the isolation, process-
ing, and characterization of EVs to yield significant results to be
applied on patients need to be urgently standardized. Specifically,
the different isolation method can yield different types of EVs and,
thus, omics studies performed on them could give incomparable
results. Besides, not all methods are applicable in a hospital setting.
With aim of contributing to this debate and in accordance to
the results of the present work, we consider that the centri13000
method is the most suitable one to be used in a hospital setting
as (a) it requires a simple infrastructure (and does not require
ultracentrifuge) that is available in any general laboratory, (b) iso-
lates EVs with similar characteristics to the ones isolated with the
standard method but in higher concentrations, (c) it recovers not
only small EVs as standard does but also the largest, and (d) in
analysis with FC and WB showed less contamination when com-
paring with centri2500. We concur with Deun and colleagues (55)
in that it is necessary for a validation of the isolation procedure
and we propose that this validation could be carried out in referent
laboratories lead by group with great expertise in the study of EVs.
The results obtained in the hospital setting should be compared
to those obtained by the reference lab to assure a quality control.
On the other, for the posterior detection and characterization of
EVs, we recommend to analyze them with at least one quantifica-
tion method (NTA or FC) and one characterization method (WB,
EM, or FC) as they provide complementary information. Figure 4
summarizes a proposed workflow based on the discussion above.
To conclude, the isolation of EVs, at least for plasma-derived
ones, through differential centrifugation at medium speed (cen-
tri13000) and their posterior analysis with at least one quantifi-
cation method (NTA, for example) and another characterization
method (FC or WB, for example) could fit in a workflow that goes
from the patient to lab and all the way back to the patient and
would contribute to face several health problems.
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